Habib is the former President & CEO of Acceleron Pharma, a company targeting leading-edge therapies for patients with serious and rare diseases, sold to Merck for $11.5B in 2021.

He currently serves as an Independent Board Director at Day One Biopharmaceuticals (NASDAQ: DAWN), Blueprint Medicines (NASDAQ: BPMC), Aerovate Therapeutics (NASDAQ: AVTE), and PepGen Inc. (NASDAQ: PEPG).  He is also a part-time Venture Partner at RA Capital Management.

Prior to joining Acceleron in 2016, Habib was President of U.S. Pharmaceuticals at Bayer AG., where he held positions of increasing responsibility during his 22-year tenure.  

Habib was recognized by Institutional Investor for three consecutive years (2019, 2020, 2021) as a top ranked mid-cap biotech CEO.

He was a board member of the Biotechnology Innovation Organization (BIO).

Habib received a B.B.A. and M.B.A. from the University of New Brunswick in Canada.